Topas Therapeutics and Boehringer Ingelheim sign multi-year collaboration
Initial focus on next generation vector-based therapeutics
26-Apr-2018 -
Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural tolerance induction capabilities of the liver, today announced that it has signed a multi-year agreement with Boehringer Ingelheim to collaborate in the field of antigen-specific tolerance ...
collaborations
regulatory T cells
research collaborations
+3